OncoSec to Present at the RHK Capital Disruptive Growth Conference on December 6, 2022 Dec 05, 2022 9:00am EST
OncoSec presents encouraging early data with TAVO™-EP combined with nivolumab (Opdivo®) in neoadjuvant melanoma Nov 15, 2022 4:45pm EST
OncoSec Announces Positive Clinical Data of the KEYNOTE-695 Trial Assessing TAVO-EP in Combination with Pembrolizumab (Keytruda®) in Patients with Advanced Melanoma Refractory to anti-PD-1 Treatment Nov 11, 2022 8:38am EST
Novel pre-clinical results regarding OncoSec's intratumoral electroporation platform were highlighted as Editor's Pick in Molecular Cancer Research Jun 24, 2022 8:00am EDT
OncoSec Receives Triple Negative Breast Cancer Foundation's Vanguard Award for Excellence in Oncology Research May 23, 2022 8:00am EDT
